BSLN Basilea Pharmaceutica AG

Basilea reports marketing authorization of antifungal Cresemba® in Brazil

Basilea reports marketing authorization of antifungal Cresemba® in Brazil

Basel, Switzerland, October 29, 2019 – Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that its partner Grupo Biotoscana S.L. (“GBT”), received the regulatory approval and marketing authorization for the antifungal Cresemba® (isavuconazole) in Brazil. GBT is Basilea’s distribution partner for Cresemba and the antibiotic Zevtera® (ceftobiprole) in Latin America.

David Veitch, Basilea's Chief Executive Officer, said: “We are very pleased with the approval of Cresemba in Brazil, which is commercially the most important market for the brand in Latin America. We are looking forward to GBT launching Cresemba in Brazil, adding yet another market towards our goal of doubling the number of countries in which Cresemba is launched to 40 by the end of 2019. The market potential in these new countries and the continued growth in markets where the brand has been launched earlier, give us continued confidence in the long-term growth potential for Cresemba."

For the 12-month period of July 2018 to June 2019, total "in-market" sales of Cresemba amounted to approximately 180 million U.S. dollars (more than 35 percent growth year-on-year).1

David Veitch commented: "It is very reassuring to see the continued strong Cresemba "in-market" sales growth for all regions where the drug is currently launched. This confirms that Cresemba is addressing a high unmet medical need. Aspergillosis and mucormycosis have a devastating effect, adding to the impact of the underlying condition in patients with cancer, diabetes or undergoing transplantations."

About Cresemba (isavuconazole)

Isavuconazole is an intravenous (i.v.) and oral azole antifungal, commercialized under the trade name Cresemba. Cresemba is approved in Brazil for patients 18 years of age and older for the treatment of invasive aspergillosis and mucormycosis.2 Cresemba is approved in 46 countries altogether and currently marketed in 38 countries, including the United States, most EU member states and several additional countries in and outside of Europe. Cresemba was reviewed under the recently introduced orphan drug legislation in Brazil and has U.S. and European orphan drug designation for its approved indications. Basilea has entered into several license and distribution agreements for isavuconazole covering the United States, Europe, China, Japan, Latin America, Asia-Pacific, the Middle East and North Africa (MENA) region, Canada, Russia, Turkey and Israel.3

About Basilea

Basilea Pharmaceutica Ltd. is a commercial stage biopharmaceutical company, focused on the development of products that address the medical challenges in the therapeutic areas of oncology and anti-infectives. With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd. and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Peer Nils Schröder, PhD

Head of Corporate Communications & Investor Relations





This press release can be downloaded from

References

1    IQVIA, June 2019. In-market sales reported as moving annual total (MAT) in U.S. Dollar corrected for currency fluctuations.

2    Brazilian Health Regulatory Agency (ANVISA), October 2019

3    The registration status and approved indications may vary from country to country.

Attachments

EN
29/10/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Basilea Pharmaceutica AG

 PRESS RELEASE

Basilea erhält weitere USD 6 Mio. von BARDA zur Weiterentwicklung des ...

Basilea erhält weitere USD 6 Mio. von BARDA zur Weiterentwicklung des neuartigen Antibiotikums Ceftibuten-Ledaborbactam Ad hoc-Mitteilung gemäss Art. 53 KR Allschwil, 25. Februar 2026 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patientinnen und Patienten zu helfen, die an schweren Infektionen durch Bakterien oder Pilze erkrankt sind, gab heute bekannt, dass die Biomedical Advanced Research and Development Authority (BARDA) der Administration for Strategic Preparedness and Response (ASPR) im U...

 PRESS RELEASE

Basilea receives further USD 6 million from BARDA to continue developm...

Basilea receives further USD 6 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, February 25, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Hea...

Basilea Pharmaceutica AG: 1 director

A director at Basilea Pharmaceutica AG sold 600 shares at 54.678CHF and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...

 PRESS RELEASE

Basilea erzielt starke Ergebnisse im Geschäftsjahr 2025 und übertrifft...

Basilea erzielt starke Ergebnisse im Geschäftsjahr 2025 und übertrifft Umsatz- und Betriebsgewinn-Guidance 15 % Anstieg der Lizenzeinnahmen 11 % Anstieg der GesamtumsätzeNettoliquidität verdreifacht Phase-3-Programm mit Fosmanogepix verläuft wie geplantGesamtumsatz und Betriebsgewinn 2026: zweistelliges Wachstum erwartetTelefonkonferenz und Webcast heute um 16 Uhr (MEZ) Ad hoc-Mitteilung gemäss Art. 53 KR Allschwil, 17. Februar 2026 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patientinnen und Patien...

 PRESS RELEASE

Basilea reports strong 2025 full-year results, surpassing revenue and ...

Basilea reports strong 2025 full-year results, surpassing revenue and operating profit guidance 15% royalty income increase 11% total revenue increaseTripled net cash position Phase 3 program with fosmanogepix progressing as plannedFinancial guidance FY 2026: Double-digit increase in total revenue and operating profitConference call and webcast today at 4 p.m. (CET) Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, February 17, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharma company committed to meeting the needs of patients with sever...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch